Newsroom

LOS ANGELES--(BUSINESS WIRE)--RESECURITY (USA) is proud to announce our new Partner Membership with the Association of Old Crows (AOC), the premier global organization dedicated to advancing electromagnetic warfare (EW) and spectrum operations. The Association of Old Crows (AOC) is an international professional organization that began in 1964 as a forum for the exchange of technical and operational information. With over 14,000 members internationally, the AOC is dedicated to advancing the art...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash. Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Forte and its board of directors violated the federa...

OMAHA, Neb.--(BUSINESS WIRE)--(BRK.A; BRK.B) – Berkshire’s operating results for the second quarter and first six months of 2026 and 2025 are summarized in the following paragraphs. However, we urge investors and reporters to read our 10-Q, which has been posted at www.berkshirehathaway.com. The limited information that follows in this press release is not adequate for making an informed investment judgment. Earnings of Berkshire Hathaway Inc. and its consolidated subsidiaries for the second qu...

維也納--(BUSINESS WIRE)--(美國商業資訊)-- 國際商會(ICC)仲裁庭就AOP Orphan Pharmaceuticals GmbH (“AOP Health”)與PharmaEssentia Corp. (“PharmaEssentia”)之間關於BESREMi® (ropeginterferon alfa-2b)的持續仲裁程序做出一項金額裁定，裁定AOP Health獲得總計約1.12億歐元賠償。該裁定將AOP Health因PharmaEssentia故意違約而提出的損害賠償請求金額確定為約8200萬歐元。同時，仲裁庭還裁定AOP Health獲得約3100萬歐元及利息，做為AOP Health在2019年至2022年期間因PharmaEssentia定價過高而多付之款項的補償。仲裁庭由此確認，PharmaEssentia在上述年份中向AOP Health收取的費用存在高達900%的超額加價。仲裁庭還確認，AOP Health有權將其欠付PharmaEssentia的約1700萬歐元利潤分成款項，與其遠超該金額的AOP Health損害賠償請求進行有效抵銷。...

ウィーン--(BUSINESS WIRE)--（ビジネスワイヤ） -- ICC仲裁裁判所は、PharmaEssentia Corp.との係争中の仲裁手続において下された損害額裁定により、AOP Orphan Pharmaceuticals GmbH（「AOP Health」）に対し、総額約1億1,200万ユーロを裁定しました。ICC仲裁裁判所は、BESREMi®（ロペグインターフェロン アルファ-2b）に関してPharmaEssentia Corp.（以下「PharmaEssentia」）との間で係争中の仲裁手続において下された損害額裁定により、AOP Orphan Pharmaceuticals GmbH（以下「AOP Health」）に対し、総額約1億1,200万ユーロを認めました。同裁定では、PharmaEssentiaによる故意の契約違反に基づくAOP Healthの損害賠償請求額を約8,200万ユーロと認定しています。また、2019年から2022年にかけての過度な価格設定によりAOP HealthがPharmaEssentiaに対して支払った超過支払額の返還として、約3,1...

VIENNA--(BUSINESS WIRE)--Un tribunale arbitrale ICC ha concesso a AOP Orphan Pharmaceuticals GmbH (“AOP Health”), un risarcimento totale di circa 112 milioni di euro nel procedimento arbitrale con PharmaEssentia Corp. (“PharmaEssentia”) riguardante BESREMi® (ropeginterferone alfa-2b). Il risarcimento quantifica le rivendicazioni dei danni di AOP Health riguardanti le violazioni intenzionali di PharmaEssentia a circa 82 milioni di euro. Il tribunale inoltre ordina il pagamento a AOP Health di ci...

维也纳--(BUSINESS WIRE)--(美国商业资讯)-- 国际商会(ICC)仲裁庭就AOP Orphan Pharmaceuticals GmbH (“AOP Health”)与PharmaEssentia Corp. (“PharmaEssentia”)之间关于BESREMi® (ropeginterferon alfa-2b)的持续仲裁程序作出了一项金额裁决，裁定AOP Health获得总计约1.12亿欧元赔偿。该裁决将AOP Health因PharmaEssentia故意违约而提出的损害赔偿请求金额确定为约8200万欧元。同时，仲裁庭还裁定AOP Health获得约3100万欧元及利息，作为AOP Health在2019年至2022年期间因PharmaEssentia定价过高而多付的款项的补偿。仲裁庭由此确认，PharmaEssentia在上述年份中向AOP Health收取的费用存在高达900%的超额加价。仲裁庭还确认，AOP Health有权将其欠付PharmaEssentia的约1700万欧元利润分成款项，与其远超该金额的AOP Health损害赔偿请求进行有效抵销...

VIENA--(BUSINESS WIRE)--Un Tribunal Arbitral de la Cámara de Comercio Internacional (CCI) ha otorgado a AOP Orphan Pharmaceuticals GmbH ("AOP Health") un total de aproximadamente 112 millones de euros en un laudo sobre la cuantía emitido en el procedimiento arbitral en curso con PharmaEssentia Corp. ("PharmaEssentia") en relación con BESREMi® (ropeginterferón alfa-2b). El laudo cuantifica las reclamaciones por daños y perjuicios de AOP Health por incumplimientos intencionados de PharmaEssentia...

WENEN--(BUSINESS WIRE)--Een ICC-arbitragetribunaal heeft AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in totaal ongeveer 112 miljoen euro toegekend in een schadevergoedingsvonnis dat is uitgesproken in de lopende arbitrageprocedure met PharmaEssentia Corp. ("PharmaEssentia") betreffende BESREMi® (ropeginterferon alfa-2b). In de uitspraak worden de schadeclaims van AOP Health wegens opzettelijke contractbreuken door PharmaEssentia becijferd op circa 82 miljoen euro. Daarnaast wordt aan AOP Hea...

WIEN--(BUSINESS WIRE)--Ein ICC-Schiedsgericht hat der AOP Orphan Pharmaceuticals GmbH („AOP Health“) in einem im laufenden Schiedsverfahren mit der PharmaEssentia Corp. („PharmaEssentia“) bezüglich BESREMi® (Ropeginterferon alfa-2b) erlassenen Schiedsspruch über die Höhe des Schadenersatzes insgesamt rund 112 Mio. EUR zugesprochen. Der Schiedsspruch beziffert die Schadensersatzansprüche von AOP Health aufgrund vorsätzlicher Vertragsverletzungen durch PharmaEssentia auf ca. 82 Mio. EUR. Zudem we...